Fondaparinux Subcutaneous Solution, Subcutaneous
Fondaparinux, a synthetic pentasaccharide, acts as a selective inhibitor of activated factor X. It works by binding selectively to antithrombin III and potentiates the neutralisation of factor Xa. This will interrupt the blood coagulation cascade and inhibit both thrombin formation and thrombus development.
Prophylaxis Of Deep Vein Thrombosis- Fondaparinux is used for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE):
- In patients undergoing hip fracture surgery, including extended prophylaxis;
- In patients undergoing hip replacement surgery;
- In patients undergoing knee replacement surgery;
- In patients undergoing abdominal surgery who are at risk for thromboembolic complications.
Treatment Of Acute Deep Vein Thrombosis: Fondaparinux is used for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium.
Treatment Of Acute Pulmonary Embolism: Fondaparinux is used for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital.
Fondaparinux is also used to associated treatment for these conditions: Acute Pulmonary Embolism, Deep Vein Thrombosis, Non ST Segment Elevation Myocardial Infarction (NSTEMI), ST Elevation Myocardial Infarction (STEMI), Unstable Angina Pectoris, Acute, superficial, symptomatic Vein Thrombosis
|Fondaparinux Other Names||Natural heparin pentasaccharide|
|Weight||10mg/0.8ml, 2.5mg/0.5ml, 5mg/0.4ml, 7.5mg/0.6ml,|
|Type||Subcutaneous Solution, Subcutaneous|
94% in vitro protein binding specifically to ATIII
|Therapeutic Class||Parenteral anti-coagulants|
|Available Country||United States|
|Last Updated:||July 1, 2021 at 6:50 pm|
Superficial vein thrombosis: 2.5 mg once daily for 30-45 days.
- 50-100 kg: 7.5 mg once daily;
- >100 kg: 10 mg once daily.
- Treatment duration: 5-9 days, or until oral anticoagulation is established.
Prophylaxis of deep vein thrombosis in abdominal and orthopaedic surgery: 2.5 mg once daily, starting 6-8 hr after surgery, continue for at least 5-9 days. In high-risk patients, 6-14 days or up to 32 days in hip fracture.
Hip-fracture, hip-replacement, or knee-replacement surgery: Anaemia, fever, nausea, oedema, constipation, rash, vomiting, insomnia, increased wound drainage, hypokalaemia, UTI, dizziness, purpura, hypotension, confusion, bullous eruption, urinary retention, haematoma, major bleeding, diarrhoea, dyspepsia, post-op haemorrhage, and headache. Treatment of venous thromboembolism: Constipation, headache, insomnia, fever, nausea, UTI, and coughing. Abdominal surgery: Post-op wound infection and haemorrhage, fever, surgical site reaction, anaemia, HTN, pneumonia, vomiting.
Patient with increased risk of haemorrhage (e.g. congenital or acquired bleeding disorders, history or active Gl ulceration, intracranial haemorrhage, recent brain, spinal or ophth surgery)
Increased risk of bleeding with (e.g. desirudin, fibrinolytic drugs, glycoprotein IIb/IIIa-receptor antagonists, heparin, heparinoids or LMWH).
- Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include ginseng, ginkgo, ginger, and garlic.
Volume of Distribution
- 7 - 11 L (healthy adults), distributed primarily in blood
Pregnancy & Breastfeeding use
Pregnancy Category B. Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).
Lactation: Unknown whether drug is excreted in milk; use with caution
Hypersensitivity. Active clinically significant bleeding, acute bacterial endocarditis.
Store below 25° C. Do not freeze.